ConsCIOUS-3: Will noradrenergic suppression reduce connected consciousness after intubation? A randomised, placebo controlled trial.
ConsCIOUS-3: Will noradrenergic suppression reduce connected consciousness after intubation?
Royal Prince Alfred Hospital
52 participants
May 26, 2022
Interventional
Conditions
Summary
ConsCIOUS-3 is a single site, randomised control trial, using the trial drug dexmedetomidine or placebo given during general anaesthetic induction. The primary objective of this study is to determine whether a commonly used anaesthetic drug and sedative, dexmedetomidine, may reduce rises in the Bispectral Index. Healthy participants, aged 18-40, will be recruited from surgical lists and enrolled prior to surgery. Data collection will occur intra-operatively, post-operatively in recovery and at 24-hours and 7-days post-operation.
Eligibility
Inclusion Criteria4
- Adults, 18 -40 years old requiring intubation for general anaesthesia
- American Society of Anaesthesiologists status (ASA) 1, 2 or 3
- Able and willing to provide informed consent, participate and comply with study requirements
- Support of treating surgical team for participant invovlement
Exclusion Criteria5
- Persons who are lactating or pregnant
- Persons with a history of allergy to dexmedetomidine
- Persons with history of heart block
- Persons with a history of psychological illness or other conditions with may interfere with their ability to understand the study requirements
- Persons with cognitive impairment that is likely to interfere with the evaluation of participant's safety and of the study outcome
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dexmedetomidine 0.5mg/kg will be given intravenously (IV) over 5 minutes prior to/during intubation during a general anaesthetic. This will be administered by the treating anaestheist and will be monitored by the principal investigator Professor Robert Sanders. Anaesthetic doctors will be trained on study protocol prior to comencement of the trial and will record the drug administration in the anaesthetic chart as dexmedetomidine/placebo. If there are any errors in administration or dose this will be reported to Professor Robert Sanders and the Research Coordinator and documented/reported as required by the local HREC.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12622000754741